Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 1/20 | 0.34 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.34 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19586263 | 0.87 | CYP4F2 (0.37) | CYP4F2CYP4A11NR1H2PKMUSP2 | |
| SCHEMBL19586015 | 0.82 | USP2 (0.47) | CYP4F2CYP4A11PKMUSP2SMN1; SMN2 | |
| SCHEMBL19586436 | 0.80 | PKM (0.34) | CYP4F2CYP4A11NR1H2PKMUSP2 | |
| SCHEMBL22018261 | 0.77 | PKM (0.46) | CYP4F2CYP4A11PKMUSP2SMN1; SMN2 | |
| SCHEMBL23390562 | 0.73 | NR1H2 (0.42) | CYP4F2CYP4A11NR1H2PKMUSP2 | |
| SCHEMBL13011470 | 0.73 | USP2 (0.40) | CYP4F2CYP4A11NR1H2PKMUSP2 | |
| SCHEMBL25591485 | 0.73 | USP2 (0.44) | CYP4F2CYP4A11NR1H2PKMUSP2 | |
| SCHEMBL22019321 | 0.73 | HDAC8 (0.34) | — | |
| SCHEMBL31171637 | 0.72 | CYP4F2 (0.53) | CYP4F2CYP4A11PKMUSP2SMN1; SMN2 | |
| SCHEMBL19585994 | 0.72 | USP2 (0.43) | CYP4F2CYP4A11NR1H2PKMUSP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11185592-B2 | Spirocyclic degronimers for target protein degradation | C4 THERAPEUTICS, INC. (US) | 2021-11-30 | — | — | US | disclosed |
| US-20210106688-A1 | SPIROCYCLIC DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | C4 THERAPEUTICS, INC. (US) | 2021-04-15 | — | — | US | disclosed |
| US-10660968-B2 | Spirocyclic degronimers for target protein degradation | C4 THERAPEUTICS, INC. (US) | 2020-05-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11185592-B2 | Spirocyclic degronimers for target protein degradation | STUB1, UBE3C, UBE3A | CYP4F2 3357/4885CYP4A11 941/4885NR1H2 309/4885 |
| US-20210106688-A1 | SPIROCYCLIC DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | STUB1, UBE3C, UBE3A | CYP4F2 3357/4885CYP4A11 941/4885NR1H2 309/4885 |
| US-10660968-B2 | Spirocyclic degronimers for target protein degradation | STUB1, UBE3C, UBE3A | CYP4F2 3357/4885CYP4A11 941/4885NR1H2 309/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.